Applied DNA Sciences (APDN) Given Daily News Impact Score of -0.10

News stories about Applied DNA Sciences (OTCMKTS:APDN) have trended somewhat negative recently, AlphaOne Sentiment Analysis reports. The research group, a service of Accern, rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Applied DNA Sciences earned a coverage optimism score of -0.10 on AlphaOne’s scale. AlphaOne also gave headlines about the technology company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Alpha One’s analysis:

Insider Buying and Selling by Quarter for Applied DNA Sciences (OTCMKTS:APDN)

Shares of Applied DNA Sciences (OTCMKTS:APDN) traded up 5.1263% on Friday, hitting $0.9987. 81,859 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $1.37 and its 200 day moving average is $1.72. Applied DNA Sciences has a 12 month low of $0.95 and a 12 month high of $3.61. The firm’s market cap is $26.32 million.

Applied DNA Sciences (OTCMKTS:APDN) last posted its earnings results on Thursday, May 11th. The technology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $1.25 million. Applied DNA Sciences had a negative net margin of 378.72% and a negative return on equity of 128.10%. The company’s revenue was up 59.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.14) earnings per share. On average, equities analysts predict that Applied DNA Sciences will post ($0.35) earnings per share for the current year.

APDN has been the topic of a number of analyst reports. ValuEngine lowered shares of Applied DNA Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Maxim Group set a $6.00 target price on shares of Applied DNA Sciences and gave the stock a “buy” rating in a research report on Thursday, April 6th.

COPYRIGHT VIOLATION WARNING: “Applied DNA Sciences (APDN) Given Daily News Impact Score of -0.10” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at

About Applied DNA Sciences

Applied DNA Sciences, Inc is engaged in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). Its principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon.

Receive News & Ratings for Applied DNA Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences Inc and related companies with's FREE daily email newsletter.

Leave a Reply